Ann: ADVENT-AML Phase 1B clinical trial update, page-92

Of course you are, your original comment clearly stated that the announcement was likely published
“with the sole intention of raising more cash and with no way of identifying if these responses were any way attributable to NK Cells.”
That strongly implies the data is being used in a misleading way — which, whether intentional or not, casts doubt on the integrity of the parties involved.

So yes, by questioning the credibility of the results and suggesting they were released purely to raise funds — despite being generated by MD Anderson and led by Dr Maiti, a respected haematologist — you are indirectly implying that they’ve allowed their names and reputations to be used in a way that lacks scientific integrity. That’s not a light accusation, even if it's couched in speculation.

As for the timing — it’s actually not unusual for biotech companies to publish interim data from Phase 1B studies, especially when early signs of efficacy are observed in a difficult-to-treat population. These kinds of updates are both expected and appropriate, provided they’re transparent about the limited sample size and context — which this one was.

The fact that Dr Maiti didn’t issue a personal comment in the media release doesn’t mean there’s something “strange” going on. Investigators often communicate through trial data and institutional channels rather than individual commentary, especially in early-stage studies.

Let’s just be careful not to confuse healthy skepticism with misplaced doubt in a reputable clinical process and respected individuals.